respiratory syncytial virus Archives -

In its first set of financial figures since spinning off its consumer health division, GSK has reported a

Record Shingrix sales help GSK raise 2022 forecasts

https://pharmaphorum.com/news/record-shingrix-sales-help-gsk-raise-2022-forecasts/

News/ News/ R&D

Ex-GSK vaccine chief to lead new UK biotech Vicebio

Phil Taylor GlaxoSmithKline, respiratory syncytial virus, vaccines, Vicebio 0 Comment

GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called

Ex-GSK vaccine chief to lead new UK biotech Vicebio

https://pharmaphorum.com/news/ex-gsk-vaccine-chief-to-lead-new-uk-biotech-vicebio/

News/ News/ Sales and Marketing

Pfizer seeks to overturn three RSV vaccine patents held by GSK

Phil Taylor GlaxoSmithKline, patent litigation, Pfizer, respiratory syncytial virus, vaccine 0 Comment

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are

Pfizer seeks to overturn three RSV vaccine patents held by GSK

https://pharmaphorum.com/news/pfizer-seeks-to-overturn-three-rsv-vaccine-patents-held-by-gsk/

News/ News/ R&D

Relief for GSK as RSV vaccine clears phase 3 test in adults

Phil Taylor Bavarian Nordic, GSK, Johnson & Johnson, Moderna, Pfizer, respiratory syncytial virus, vaccine 0 Comment

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the

Relief for GSK as RSV vaccine clears phase 3 test in adults

https://pharmaphorum.com/news/relief-for-gsk-as-rsv-vaccine-clears-phase-3-test-in-adults/

News/ News/ R&D

AZ, Sanofi build case for one-shot RSV antibody

Phil Taylor AstraZeneca, infectious disease, nirsevimab, paediatrics, respiratory syncytial virus, Sanofi 0 Comment

A pooled analysis of data for AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) antibody nirsevimab has concluded that

AZ, Sanofi build case for one-shot RSV antibody

https://pharmaphorum.com/news/az-sanofi-build-case-for-one-shot-rsv-antibody/

News/ News/ R&D

Pfizer bulks up in RSV with $525m takeover of ReViral

Phil Taylor antiviral, infectious disease, M&A, paediatrics, Pfizer, respiratory syncytial virus, ReViral 0 Comment

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a

Pfizer bulks up in RSV with $525m takeover of ReViral

https://pharmaphorum.com/news/pfizer-bulks-up-in-rsv-with-525m-takeover-of-reviral/

News/ News/ Sales and Marketing

Trailing its RSV vaccine rivals, Bavarian Nordic cuts China deal

Phil Taylor Bavarian Nordic, GlaxoSmithKline, Johnson & Johnson, licensing, Moderna, Nuance Pharma, Pfizer, respiratory syncytial virus, vaccine 0 Comment

Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian

Trailing its RSV vaccine rivals, Bavarian Nordic cuts China deal

https://pharmaphorum.com/news/trailing-its-rsv-vaccine-rivals-bavarian-nordic-cuts-china-deal/

Market Access/ News/ News

After GSK stumble, Pfizer moves forward with RSV vaccine

Phil Taylor AstraZeneca, GlaxoSmithKline, nirsevimab, Pfizer, respiratory syncytial virus, Sanofi, SOBI, Synagis, vaccine 0 Comment

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant

After GSK stumble, Pfizer moves forward with RSV vaccine

https://pharmaphorum.com/news/after-gsk-stumble-pfizer-moves-forward-with-rsv-vaccine/

News/ News/ R&D

GSK’s halts RSV vaccine trials in pregnant women after pause

Phil Taylor GlaxoSmithKline, pregnancy, respiratory syncytial virus, safety, vaccine 0 Comment

It looks like GlaxoSmithKline’s concerns about its respiratory syncytial virus (RSV) vaccine in pregnant women aren’t going to

GSK’s halts RSV vaccine trials in pregnant women after pause

https://pharmaphorum.com/news/gsks-halts-rsv-vaccine-trials-in-pregnant-women-after-pause/

Trending

respiratory syncytial virus

Login